The Canada-based company Tilray, a global pioneer in cannabis research, cultivation, production, and distribution said Monday it signed an import-export agreement with an Israeli company, Canndoc, for medical cannabis. Under the terms of the deal, Tilray is to ship up to 2.5 metric tons of product to the Middle Eastern country. Tilray said the delivery, which will originate from company facilities in Portugal, should arrive early this month. It will be sold in Israeli pharmacies.
Although the temperate Israeli climate is suitable for growing cannabis, the country is currently experiencing a shortage of product. Some claim that this arises from reforms enacted last May, which aim to shift the point of sale to licensed pharmacies rather than directly from growers. These reforms also mandate that growers conform to Good Manufacturing Practices (GMP) standards.
https://www.fool.com/news/2020/01/03/tilray-t...pot-d.aspx
Founded in 2008 in Herzliya, Israel, Canndoc is an IMCA (Israeli Medical Cannabis Agency) permit holder for the manufacturing of medical cannabis in Israel and is the country’s first public company in the field. Canndoc has been active for more than 10 years in researching, developing, cultivating and marketing medical cannabis to thousands of patients under a wide range of medical indications approved by Israel’s Ministry of Health.
https://www.bakersfield.com/ap/news/correctin...33ac5.html
Canndoc is bringing medical cannabis into the 21ˢᵗ century with pharma-grade treatments for patients. Canndoc’s GMP standard products are prescribed for a range of indications including Neuropathic pain, Relief of pain of cancerous source, Inflammatory bowel disease, Post-traumatic stress disorder, Parkinson’s, Epileptic seizures, adult epilepsy, fibromyalgia, neuropathic pain, side effects of chemotherapy, parkinson, rheumatoid arthritis, radicular pain, and lumbar radiculopathy.
For more than 12 years Canndoc’s research has contributed to the advancement of medical cannabis through cutting-edge therapeutic development and building a portfolio of GMP products with efficacy as a top priority. We’re focused on validating our clinical significance through clinical trials with hospitals and universities.
https://www.canndoc-pharma.com/
Canndoc is one of the first licensed producers, with its GMP-approved medical cannabis Rx products being sold in pharmacies. The engagement in this distribution agreement will broaden Canndoc's ability to distribute GMP products to its patients within the S.L.E. pharmacy network throughout Israel. In addition, S.L.E. will provide Canndoc significant logistical capabilities in the future supporting Canndoc's ability to export its products to countries with consistent regulation for the sale and distribution of cannabis products for medical use.
https://markets.businessinsider.com/news/stoc...1028522575
HERZLIYA, Israel, Sept. 13, 2019 /PRNewswire/ -- InterCure (TASE: INCR), announced that its 100% owned subsidiary Canndoc has entered into a strategic distribution agreement with Salomon, Levin, Elstein (S.L.E.,) which is owned by Teva Pharmaceuticals Industries (NYSE: and TASE: TEVA).
InterCure holds two other biotech investments: i) 12.27% stake in Regenera, clinical-stage biopharmaceutical company focused on developing a novel drug for neurological disorders currently at Phase 3 clinical trial in NAION after receiving FDA Fast Track designation and ii) 8.88% stake in Novellus, a Jerusalem based company, developing a novel technology for precision oncology therapies.
https://markets.businessinsider.com/news/stoc...1028522575
Although the temperate Israeli climate is suitable for growing cannabis, the country is currently experiencing a shortage of product. Some claim that this arises from reforms enacted last May, which aim to shift the point of sale to licensed pharmacies rather than directly from growers. These reforms also mandate that growers conform to Good Manufacturing Practices (GMP) standards.
https://www.fool.com/news/2020/01/03/tilray-t...pot-d.aspx
Founded in 2008 in Herzliya, Israel, Canndoc is an IMCA (Israeli Medical Cannabis Agency) permit holder for the manufacturing of medical cannabis in Israel and is the country’s first public company in the field. Canndoc has been active for more than 10 years in researching, developing, cultivating and marketing medical cannabis to thousands of patients under a wide range of medical indications approved by Israel’s Ministry of Health.
https://www.bakersfield.com/ap/news/correctin...33ac5.html
Canndoc is bringing medical cannabis into the 21ˢᵗ century with pharma-grade treatments for patients. Canndoc’s GMP standard products are prescribed for a range of indications including Neuropathic pain, Relief of pain of cancerous source, Inflammatory bowel disease, Post-traumatic stress disorder, Parkinson’s, Epileptic seizures, adult epilepsy, fibromyalgia, neuropathic pain, side effects of chemotherapy, parkinson, rheumatoid arthritis, radicular pain, and lumbar radiculopathy.
For more than 12 years Canndoc’s research has contributed to the advancement of medical cannabis through cutting-edge therapeutic development and building a portfolio of GMP products with efficacy as a top priority. We’re focused on validating our clinical significance through clinical trials with hospitals and universities.
https://www.canndoc-pharma.com/
Canndoc is one of the first licensed producers, with its GMP-approved medical cannabis Rx products being sold in pharmacies. The engagement in this distribution agreement will broaden Canndoc's ability to distribute GMP products to its patients within the S.L.E. pharmacy network throughout Israel. In addition, S.L.E. will provide Canndoc significant logistical capabilities in the future supporting Canndoc's ability to export its products to countries with consistent regulation for the sale and distribution of cannabis products for medical use.
https://markets.businessinsider.com/news/stoc...1028522575
HERZLIYA, Israel, Sept. 13, 2019 /PRNewswire/ -- InterCure (TASE: INCR), announced that its 100% owned subsidiary Canndoc has entered into a strategic distribution agreement with Salomon, Levin, Elstein (S.L.E.,) which is owned by Teva Pharmaceuticals Industries (NYSE: and TASE: TEVA).
InterCure holds two other biotech investments: i) 12.27% stake in Regenera, clinical-stage biopharmaceutical company focused on developing a novel drug for neurological disorders currently at Phase 3 clinical trial in NAION after receiving FDA Fast Track designation and ii) 8.88% stake in Novellus, a Jerusalem based company, developing a novel technology for precision oncology therapies.
https://markets.businessinsider.com/news/stoc...1028522575
4
